M-001 is a vaccine candidate designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza.
BiondVax's proprietary technology utilizes a unique combination of conserved and common influenza virus peptides intended to stimulate both arms of the immune system for a cross-protecting and long-lasting effect.
In a total of 6 completed Phase 1/2 and Phase 2 clinical trials, covering 698 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic.
The ongoing pivotal Phase 3 clinical trial aims to assess the safety and effectiveness of M-001 in reducing flu illness and severity.
BiondVax (NASDAQ: BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine.